Publication date: October 2026 Source: Clinical Lymphoma Myeloma and Leukemia, Volume 26, Issue 10 Author(s): Cheryl H. Chang, Allison O. Taylor, Nia M. Mitchell, Susan C. Locke, Jesse D. Troy, Rebecca P. Bystrom, Harry P. Erba, Sanghee Hong, Chenyu Lin, Thomas W. LeBlanc
Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026002430?dgcid=rss_sd_all
Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026002430?dgcid=rss_sd_all
“Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article99936,
title = {Real-World Outcomes in First-Line Venetoclax-Based Therapy in Patients With AML Ineligible for Intensive Chemotherapy: A Single Center Study},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026002430?dgcid=rss_sd_all}
}